When is XERS's latest earnings report released?
The most recent financial report for Xeris biopharma holdings, inc. (XERS) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating XERS's short-term business performance and financial health. For the latest updates on XERS's earnings releases, visit this page regularly.
What is the operating profit of XERS?
According to the latest financial report, Xeris biopharma holdings, inc. (XERS) reported an Operating Profit of 16.77M with an Operating Margin of 19.55% this period, representing a growth of 152.21% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
How is XERS's revenue growth?
In the latest financial report, Xeris biopharma holdings, inc. (XERS) announced revenue of 85.81M, with a Year-Over-Year growth rate of 37.06%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
How much debt does XERS have?
As of the end of the reporting period, Xeris biopharma holdings, inc. (XERS) had total debt of 37.76M, with a debt ratio of 0.1. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
How much cash does XERS have?
At the end of the period, Xeris biopharma holdings, inc. (XERS) held Total Cash and Cash Equivalents of 111.04M, accounting for 0.29 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Is XERS's EPS continuing to grow?
According to the past four quarterly reports, Xeris biopharma holdings, inc. (XERS)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 0.07. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of XERS?
Xeris biopharma holdings, inc. (XERS)'s Free Cash Flow (FCF) for the period is 0, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 318.79% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
What are the PEG ratio and PE ratio of XERS?
The latest valuation data shows Xeris biopharma holdings, inc. (XERS) has a Price-To-Earnings (PE) ratio of 29.39 and a Price/Earnings-To-Growth (PEG) ratio of 0.01. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.
